2020 FDA TIDES (Peptides and Oligonucleotides) Harvest

2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Musaimi, Othman, Al Shaer, Danah, Albericio, Fernando, de la Torre, Beatriz G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918236/
https://www.ncbi.nlm.nih.gov/pubmed/33670364
http://dx.doi.org/10.3390/ph14020145
_version_ 1783657880238424064
author Al Musaimi, Othman
Al Shaer, Danah
Albericio, Fernando
de la Torre, Beatriz G.
author_facet Al Musaimi, Othman
Al Shaer, Danah
Albericio, Fernando
de la Torre, Beatriz G.
author_sort Al Musaimi, Othman
collection PubMed
description 2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
format Online
Article
Text
id pubmed-7918236
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79182362021-03-02 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest Al Musaimi, Othman Al Shaer, Danah Albericio, Fernando de la Torre, Beatriz G. Pharmaceuticals (Basel) Review 2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling the global health crisis. The US Food and Drug Administration (FDA) has approved 53 new drug entities, six of which fall in the peptides and oligonucleotides (TIDES) category. The number of authorizations for these kinds of drugs has been similar to that of previous years, thereby reflecting the consolidation of the TIDES market. Here, the TIDES approved in 2020 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects. MDPI 2021-02-11 /pmc/articles/PMC7918236/ /pubmed/33670364 http://dx.doi.org/10.3390/ph14020145 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Al Musaimi, Othman
Al Shaer, Danah
Albericio, Fernando
de la Torre, Beatriz G.
2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
title 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
title_full 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
title_fullStr 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
title_full_unstemmed 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
title_short 2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
title_sort 2020 fda tides (peptides and oligonucleotides) harvest
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918236/
https://www.ncbi.nlm.nih.gov/pubmed/33670364
http://dx.doi.org/10.3390/ph14020145
work_keys_str_mv AT almusaimiothman 2020fdatidespeptidesandoligonucleotidesharvest
AT alshaerdanah 2020fdatidespeptidesandoligonucleotidesharvest
AT albericiofernando 2020fdatidespeptidesandoligonucleotidesharvest
AT delatorrebeatrizg 2020fdatidespeptidesandoligonucleotidesharvest

Ejemplares similares